Lucira Health, Inc. Form 8-K (May 28, 2021)

Summary

Current report on Form 8-K of Lucira Health, Inc. dated May 28, 2021, reporting under Item 8.01. The company states that on May 28, 2021 it issued a press release announcing that Kevin Collins has accepted the position of Chief Revenue Officer, with a first date of employment of May 27, 2021. The press release is furnished as Exhibit 99.1 and is dated May 28, 2021. The report states that the information is furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. The signature block is Daniel George, Chief Financial Officer, dated May 28, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" lhdx-8k_20210528.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 28, 2021

Lucira Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-39976 | 27-2491037
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
1412 62nd Street Emeryville, California | 94608
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (510) 350-8071

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | LHDX | Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 ( § 230.405 of this chapter) or Rule 12b – 2 of the Securities Exchange Act of 1934 ( § 240.12b – 2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other events.

On May 28, 2021, Lucira Health, Inc. (the “Company”) issued a press release announcing that Kevin Collins has accepted the position of Chief Revenue Officer. His first date of employment was May 27, 2021. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

The information contained herein and the accompanying exhibit are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description
99.1 | Press Release of Lucira Health, Inc., dated May 28, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lucira Health, Inc.
Date: May 28, 2021 | By: | /s/ Daniel George
Daniel George Chief Financial Officer

File and source

File

SEC_LHDX_8-K_filed2021-05-28_0001564590-21-030699.htm

Size

34,481 bytes

SHA-256

f8b3ae7bf30c464a470f9fd7d0e37da1ccec3bcce5602b28e037524772de40d6

Our copy

SEC_LHDX_8-K_filed2021-05-28_0001564590-21-030699.htm

Original

www.sec.gov